licensing agreement

The University of North Carolina at Chapel Hill's technology is based on set of patient-cell derived gene signatures for classifying four pancreatic subtypes.

Fleury will integrate IDbyDNA's Explify platform into its own laboratory workflow and develop a full suite of Explify-based clinical testing.

Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.

Expedeon's colloidal gold is an aqueous suspension of uniform, spherical metallic nanoparticles that can conjugate to antibodies and antigens.

The agreement will enable Biocartis to commercialize the EGFR S492R resistance mutation as part of its liquid and solid biopsy RUO assays.

LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.

The company said it plans to use the technology to derive clinical insights from the large-scale proteomic datasets generated by its SomaScan platform.

The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.

The NMI Natural and Medical Sciences Institute at the university and its affiliate will use the patents to expand their cell-based research service offerings.